

Revision date: 05-Mar-2008

Version: 1.0

Page 1 of 11

## 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222 Pfizer Ltd Ramsgate Road Sandwich, Kent CT13 9NJ United Kingdom +00 44 (0)1304 616161

Emergency telephone number: CHEMTREC (24 hours): 1-800-424-9300 Contact E-Mail: pfizer-MSDS@pfizer.com Emergency telephone number: ChemSafe (24 hours): +44 (0)208 762 8322

# Material Name: Mefenamic Acid Oral Suspension

Trade Name:	Ponstan; Ponstyl
Chemical Family:	Not determined
Intended Use:	Pharmaceutical product used as non-steroidal, anti-inflammatory drug (nsaid)

# 2. HAZARDS IDENTIFICATION

Appearance:	Off-white creamy suspension
Statement of Hazard:	Non-hazardous in accordance with international standards for workplace safety.
Additional Hazard Information: Short Term:	May be barmful if swallowed. May cause allergic reactions in susceptible individuals
Short renn.	May be harmful if swallowed. May cause allergic reactions in susceptible individuals. Individuals sensitive to this chemical or other materials in its chemical class may develop allergic reactions.
Long Term:	Repeat-dose studies in animals have shown a potential to cause adverse effects on gastrointestinal system, liver, kidneys, heart.
Known Clinical Effects:	Adverse effects associated with the therapeutic use of mefenamic acid include serious gastrointestinal toxicity such as bleeding, ulceration, and perforation and kidney toxicity. Dizziness, headaches, anemia, increased bleeding time, rashes, and liver effects have also been reported. Other nonsteroidal anti-inflammatory drugs (NSAIDs) are known to impact delivery, late fetal development, and lactation.
EU Indication of danger:	Not classified
Australian Hazard Classification (NOHSC):	Non-Hazardous Substance. Non-Dangerous Goods.
Note:	This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

#### Material Name: Mefenamic Acid Oral Suspension Revision date: 05-Mar-2008

# 3. COMPOSITION/INFORMATION ON INGREDIENTS

Ingredient	CAS Number	EU EINECS/ELINCS List	Classification	%
Mefenamic Acid	61-68-7	200-513-1	Repr. Cat.3;R63 Xn;R22	1
Sodium hydroxide	1310-73-2	215-185-5	C;R35	<1
Hydrochloric Acid	7647-01-0	231-595-7	C;R35 T;R23	<1
Sucrose	57-50-1	200-334-9	Not Listed	*
Alcohol	64-17-5	200-578-6	F;R11	0.5

Ingredient	CAS Number	EU EINECS/ELINCS List	Classification	%
Povidone	9003-39-8	Not listed	Not Listed	*
Gluconolactone	90-80-2	202-016-5	Not Listed	*
Magnesium aluminum silicate	1327-43-1	215-478-8	Not Listed	*
Sodium benzoate	532-32-1	208-534-8	Not Listed	*
Sodium saccharin	128-44-9	204-886-1	Not Listed	*
Carboxymethylcellulose sodium	9004-32-4	Not listed	Not Listed	*
Sorbitol solution	50-70-4	200-061-5	Not Listed	*
Water	7732-18-5	231-791-2	Not Listed	*
Flavor	NOT ASSIGNED	Not listed	Not Listed	*

**Additional Information:** 

\* Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

### For the full text of the R phrases mentioned in this Section, see Section 16

### 4. FIRST AID MEASURES

Eye Contact:	Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.
Skin Contact:	Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.
Ingestion:	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.
Inhalation:	Remove to fresh air and keep patient at rest. Seek medical attention immediately.
Symptoms and Effects of Exposure:	For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

# **5. FIRE FIGHTING MEASURES**

**Extinguishing Media:** 

Carbon dioxide, dry chemical, or foam

#### Material Name: Mefenamic Acid Oral Suspension Revision date: 05-Mar-2008

Hazardous Combustion Products:	Emits toxic fumes of carbon monoxide, carbon dioxide, and nitrogen oxides.	
Fire Fighting Procedures:	During all fire fighting activities, wear appropriate protective equipment, including self- contained breathing apparatus.	
Fire / Explosion Hazards:	Fine particles (such as dust and mists) may fuel fires/explosions.	
6. ACCIDENTAL RELEASE MEASURES		

Health and Safety Precautions:	Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.
Measures for Cleaning / Collecting:	Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.
Measures for Environmental Protections:	Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.
Additional Consideration for Large Spills:	Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.
7. HANDLING AND STORAGE	

General Handling:	Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling.
Storage Conditions:	Store as directed by product packaging.

# 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

Mefenamic Acid	
Pfizer OEL TWA-8 Hr:	3000 μg/m³
Sadium hudrovida	
Sodium hydroxide	
ACGIH Ceiling Threshold Limit:	= 2 mg/m <sup>3</sup> Ceiling
Australia PEAK	= 2 mg/m³ Peak
Austria OEL - MAKs	= 2 mg/m <sup>3</sup> MAK
Belgium OEL - TWA	= 2 mg/m <sup>3</sup> TWA
Bulgaria OEL - TWA	= 2.0 mg/m <sup>3</sup> TWA
Czech Republic OEL - TWA	= 1 mg/m <sup>3</sup> TWA
Finland OEL - TWA	= 2 mg/m <sup>3</sup> TWA
France OEL - TWA	= 2 mg/m <sup>3</sup> VME
Greece OEL - TWA	= 2 mg/m <sup>3</sup> TWA
Hungary OEL - TWA	= 2 mg/m <sup>3</sup> TWA
Latvia OEL - TWA	= 0.5 mg/m <sup>3</sup> TWA
OSHA - Final PELS - TWAs:	2 mg/m <sup>3</sup>
Poland OEL - TWA	= 0.5 mg/m <sup>3</sup> NDS
Slovakia OEL - TWA	= 2 mg/m <sup>3</sup> TWA
Slovenia OEL - TWA	= 2 mg/m <sup>3</sup> TWA
Sweden OEL - TWAs	= 1 mg/m <sup>3</sup> LLV

Hydrochloric Acid

except .gamma.-Aluminum oxide

Material Name: Mefenamic Acid Oral Suspension Revision date: 05-Mar-2008

Page 4 of 11 Version: 1.0

ACGIH Ceiling Threshold Limit:	= 2 ppm Ceiling
Australia PEAK	= 5 ppm Peak
	= 7.5 mg/m <sup>3</sup> Peak
Austria OEL - MAKs	= 5 ppm MAK
	$= 8 \text{ mg/m}^3 \text{ MAK}$
Belgium OEL - TWA	= 5 ppm TWA
	$= 8 \text{ mg/m}^3 \text{ TWA}$
Bulgaria OEL - TWA	= 8.0 mg/m <sup>3</sup> TWA
Cyprus OEL - TWA	= 5.0 ppm TWA
<b>51</b>	$= 8.0 \text{ mg/m}^3 \text{ TWA}$
Czech Republic OEL - TWA	$= 8 \text{ mg/m}^3 \text{ TWA}$
Estonia OEL - TWA	= 5 ppm TWA
	= 8 mg/m <sup>3</sup> TWA
Germany - TRGS 900 - TWAs	= 2 ppm TWA
	= 3 mg/m <sup>3</sup> TWA
Greece OEL - TWA	= 5 ppm TWA
	$= 7 \text{ mg/m}^3 \text{ TWA}$
Hungary OEL - TWA	$= 8 \text{ mg/m}^3 \text{ TWA}$
Ireland OEL - TWAs	= 5 ppm TWA
	$= 7 \text{ mg/m}^3 \text{ TWA}$
Italy OEL - TWA	= 5 ppm TWA
	$= 8 \text{ mg/m}^3 \text{ TWA}$
Latvia OEL - TWA	= 5 ppm TWA
	$= 8 \text{ mg/m}^3 \text{ TWA}$
Lithuania OEL - TWA	= 5 ppm IPRV
	= 8 mg/m <sup>3</sup> IPRV
Luxembourg OEL - TWA	= 5 ppm TWA
	$= 8 \text{ mg/m}^3 \text{ TWA}$
Malta OEL - TWA	= 5 ppm TWA
	$= 8 \text{ mg/m}^3 \text{ TWA}$
Netherlands OEL - TWA	= 5 ppm MAC
	$= 8 \text{ mg/m}^3 \text{ MAC}$
Poland OEL - TWA	$= 5 \text{ mg/m}^3 \text{ NDS}$
Romania OEL - TWA	= 5 ppm TWA
	= 8 mg/m <sup>3</sup> TWA
Slovakia OEL - TWA	= 5 ppm TWA
	$= 8.0 \text{ mg/m}^3 \text{ TWA}$
Slovenia OEL - TWA	= 5 ppm TWA anhydrous
Slovenia OEE - TWA	= 8 mg/m <sup>3</sup> TWA anhydrous
Spain OEL - TWA	= 5 ppm VLA-ED
	= 7.6 mg/m <sup>3</sup> VLA-ED
Magnesium aluminum silicate	
Bulgaria OEL - TWA	= 1.5 mg/m <sup>3</sup> TWA
	$= 10.0 \text{ mg/m}^3 \text{ TWA}$
Czech Republic OEL - TWA	= 10.0 mg/m <sup>3</sup> TWA except for gamma Al2O3
Slovakia OEL - TWA	= 6 mg/m <sup>3</sup> TWA except .gammaAluminum ox
Sucrose	
ACGIH Threshold Limit Value (TWA)	= 10 mg/m³ TWA
Australia TWA	= 10 mg/m <sup>3</sup> TWA
Belgium OEL - TWA	= 10 mg/m <sup>3</sup> TWA
-	= 10.0 mg/m <sup>3</sup> TWA
Bulgaria OEL - TWA	
Estonia OEL - TWA	= 10 mg/m <sup>3</sup> TWA
France OEL - TWA	= 10 mg/m <sup>3</sup> VME

#### Material Name: Mefenamic Acid Oral Suspension Revision date: 05-Mar-2008

Page 5 of 11 Version: 1.0

Ireland OEL - TWAs	= 10 mg/m <sup>3</sup> TWA
Lithuania OEL - TWA	= 10 mg/m <sup>3</sup> IPRV
OSHA - Final PELS - TWAs:	= 15 mg/m <sup>3</sup> TWA total
	$= 5 \text{ mg/m}^3 \text{ TWA}$
Portugal OEL - TWA	$= 10 \text{ mg/m}^3 \text{ TWA}$
Slovakia OEL - TWA	$= 6 \text{ mg/m}^3 \text{ TWA}$
Spain OEL - TWA	= 10 mg/m <sup>3</sup> VLA-ED
Spain OEL - TWA	= TO THE/THE VEA-ED
Alcohol	
ACGIH Threshold Limit Value (TWA)	= 1000 ppm TWA
Australia TWA	= 1000 ppm TWA = 1000 ppm TWA
Australia TWA	$= 1880 \text{ mg/m}^3 \text{ TWA}$
	•
Austria OEL - MAKs	= 1000 ppm MAK = 1900 mg/m³ MAK
	•
Belgium OEL - TWA	= 1000 ppm TWA = 1007 mg/m <sup>3</sup> TM/A
	= 1907 mg/m <sup>3</sup> TWA
Bulgaria OEL - TWA	$= 1000.0 \text{ mg/m}^3 \text{TWA}$
Czech Republic OEL - TWA	$= 1000 \text{ mg/m}^3 \text{TWA}$
Denmark OEL - TWA	= 1000 ppm TWA
	$= 1900 \text{ mg/m}^3 \text{ TWA}$
Estonia OEL - TWA	$= 1000 \text{ mg/m}^3 \text{ TWA}$
Finland OFL TMA	= 500 ppm TWA
Finland OEL - TWA	= 1000 ppm TWA
	= 1900 mg/m <sup>3</sup> TWA
France OEL - TWA	= 1000 ppm VME
Commence TRCS 000 TWA	= 1900 mg/m <sup>3</sup> VME
Germany - TRGS 900 - TWAs	= 500  ppm TWA
	= 960 mg/m <sup>3</sup> TWA
Greece OEL - TWA	= 1000 ppm TWA
	= 1900 mg/m <sup>3</sup> TWA
Hungary OEL - TWA	= 1900 mg/m <sup>3</sup> TWA
Ireland OEL - TWAs	= 1000 ppm TWA
	= 1900 mg/m <sup>3</sup> TWA
Latvia OEL - TWA	= 1000 mg/m <sup>3</sup> TWA
Lithuania OEL - TWA	= 1000 mg/m <sup>3</sup> IPRV
	= 500 ppm IPRV
Netherlands OEL - TWA	$= 1000 \text{ mg/m}^3 \text{ MAC}$
	= 500 ppm MAC
OSHA - Final PELS - TWAs:	= 1000 ppm TWA
	= 1900 mg/m <sup>3</sup> TWA
Poland OEL - TWA	= 1900 mg/m <sup>3</sup> NDS
Portugal OEL - TWA	= 1000 ppm TWA
Romania OEL - TWA	= 1000 ppm TWA
	= 1900 mg/m <sup>3</sup> TWA
Slovakia OEL - TWA	= 500 ppm TWA
	= 960 mg/m <sup>3</sup> TWA
Slovenia OEL - TWA	= 1000 ppm TWA
	= 1900 mg/m <sup>3</sup> TWA
Spain OEL - TWA	= 1000 ppm VLA-ED
	= 1910 mg/m <sup>3</sup> VLA-ED
Sweden OEL - TWAs	$= 1000 \text{ mg/m}^3 \text{ LLV}$
	= 500 ppm LLV

#### **Analytical Method:**

Analytical method available for Mefenamic Acid. Contact Pfizer Inc for further information.

#### Material Name: Mefenamic Acid Oral Suspension Revision date: 05-Mar-2008

Engineering Controls:	Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.
Personal Protective Equipment:	
Hands:	Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.
Eyes:	Wear safety glasses or goggles if eye contact is possible.
Skin:	Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.
Respiratory protection:	If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

# 9. PHYSICAL AND CHEMICAL PROPERTIES:

Physical State:	Creamy suspension	Color:	Off-white
Molecular Formula:	Mixture	Molecular Weight:	Mixture
Solubility: pH: Specific Gravity:	Soluble: Water 4.9-5.1 1.12-1.14(25 °C)		

# 10. STABILITY AND REACTIVITY Stability: Stable under normal conditions of use. Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions. Incompatible Materials: As a precautionary measure, keep away from strong oxidizers Polymerization: Will not occur

## **11. TOXICOLOGICAL INFORMATION**

**General Information:** The information included in this section describes the potential hazards of the individual ingredients.

#### Acute Toxicity: (Species, Route, End Point, Dose)

#### **Mefenamic Acid**

Mouse Oral LD50 525 mg/kg Rat Oral LD50 740 mg/kg Mouse IV LD50 96 mg/kg Rat IV LD50 112 mg/kg

#### Sucrose

Rat Oral LD50 29.7 g/kg

#### Sodium benzoate

Rat Oral LD50 4,070 mg/kg Mouse Oral LD50 1600 mg/kg

#### Alcohol

PZ00586

Material Name: Mefenamic Acid Oral Suspension Revision date: 05-Mar-2008

Page 7 of 11 Version: 1.0

Rat Inhalation LC50 20,000 mg/L

#### Povidone

Rat Oral LD50 100 g/kg

#### Sodium hydroxide

Mouse IP LD50 40 mg/kg

#### Sodium saccharin

Mouse Oral LD50 17.5 g/kg Rat Oral LD50 14.2 - 17 g/kg Rat Intraperitoneal LD50 7100 mg/kg

#### Carboxymethylcellulose sodium

MouseOralLD50> 27,000mg/kgRatOralLD5027,000mg/kgRabbitDermalLD50> 2000mg/kg

#### Sorbitol solution

Rat Oral LD50 15,900 mg/kg Mouse Oral LD50 17,800 mg/kg Acute Toxicity Comments:

A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

#### Irritation / Sensitization: (Study Type, Species, Severity)

#### Alcohol

Eye Irritation Rabbit Severe

#### Sodium hydroxide

Eye Irritation Rabbit Severe Skin Irritation Rabbit Severe

#### Hydrochloric Acid

Skin IrritationSevereEye IrritationSevere

#### Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

#### Mefenamic Acid

78 Week(s) Rat Oral 25 mg/kg/day NOEL Kidney, Gastrointestinal System
1 Year(s) Dog Oral 200 mg/kg/day LOAEL Kidney, Liver
2 Year(s) Monkey No route specified 200 mg/kg/day NOAEL Kidney, Liver, Gastrointestinal system, Heart

#### Sodium benzoate

10 Day(s)RatOral27370 mg/kgLOAELLiver, Blood10 Day(s)MouseOral45 g/kgLOAELLiver, Kidney, Blood, Ureter, Bladder

#### Sodium saccharin

36 Week(s) Rat Oral 756 g/kg LOAEL Kidney, Ureter, Bladder 54 Day(s) Rat Oral 32400 mg/kg LOAEL Immune system

#### Carboxymethylcellulose sodium

13 Week(s) Rat Oral 227 g/kg LOAEL Liver, Kidney, Ureter, Bladder

# Material Name: Mefenamic Acid Oral Suspension Revision date: 05-Mar-2008

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))			
Mefenamic Acid Embryo / Fetal Development Reproductive & Fertility Rat Embryo / Fetal Development Embryo / Fetal Development	Mouse No route specified < 3500 mg/day LOEL Teratogenic No route specified 8.75-17.5 g/day NOEL No effects at maximum dose Rat No route specified Not Teratogenic Rabbit No route specified Not Teratogenic		
<b>Sodium benzoate</b> Embryo / Fetal Development	Rat Oral 44 g/kg LOEL Developmental toxicity		
Carcinogen Status:	None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.		
Povidone IARC:	Group 3 (Not Classifiable)		
Hydrochloric Acid IARC:	Group 3 (Not Classifiable)		
Sodium saccharin IARC:	Group 3 (Not Classifiable)		

12. ECOLOGICAL INFORMATION		

**Environmental Overview:** The environmental characteristics of this mixture have not been fully evaluated. Releases to the environment should be avoided.

# 13. DISPOSAL CONSIDERATIONS

**Disposal Procedures:** Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered.

## **14. TRANSPORT INFORMATION**

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

# **15. REGULATORY INFORMATION**

EU Indication of danger:

Not classified

#### Material Name: Mefenamic Acid Oral Suspension Revision date: 05-Mar-2008

Page 9 of 11 Version: 1.0

**OSHA Label:** Non-hazardous in accordance with international standards for workplace safety.

### Canada - WHMIS: Classifications

#### WHMIS hazard class:

Class D, Division 2, Subdivision A



Mefenamic Acid Australia (AICS): Standard for the Uniform Scheduling for Drugs and Poisons: EU EINECS/ELINCS List	Present Schedule 2 Schedule 4 200-513-1
Povidone Inventory - United States TSCA - Sect. 8(b)	XU
Australia (AICS):	Present
Cadium hudravida	
Sodium hydroxide CERCLA/SARA Hazardous Substances and their Reportable Quantities:	= 1000 lb final RQ = 454 kg final RQ
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling	Schedule 5
for Drugs and Poisons: EU EINECS/ELINCS List	Schedule 6 215-185-5
Gluconolactone	
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS): EU EINECS/ELINCS List	Present 202-016-5
	202 010 0
Hydrochloric Acid	
CERCLA/SARA 313 Emission reporting	= 1.0 % de minimis concentration acid aerosols including mists, vapors, gas, fog, and other airborne forms of any particle size
CERCLA/SARA Hazardous Substances	= 2270 kg final RQ
and their Reportable Quantities:	= 5000 lb final RQ
CERCLA/SARA - Section 302 Extremely Hazardous TPQs	= 500 lb TPQ gas only
CERCLA/SARA - Section 302 Extremely Hazardous Substances EPCRA RQs	= 5000 lb EPCRA RQ gas only
Inventory - United States TSCA - Sect. 8(b)	Т
Australia (AICS):	Present
Standard for the Uniform Scheduling	Schedule 5
for Drugs and Poisons: EU EINECS/ELINCS List	Schedule 6 231-595-7
	201-000-1

# Material Name: Mefenamic Acid Oral Suspension Revision date: 05-Mar-2008

Page 10 of 11 Version: 1.0

Magnesium aluminum silicate Inventory - United States TSCA - Sect. 8(b) Australia (AICS): EU EINECS/ELINCS List	Present Present 215-478-8
Sodium benzoate Inventory - United States TSCA - Sect. 8(b) Australia (AICS): EU EINECS/ELINCS List	Present Present 208-534-8
Sodium saccharin Inventory - United States TSCA - Sect. 8(b) Australia (AICS): EU EINECS/ELINCS List	Present Present 204-886-1
Carboxymethylcellulose sodium Inventory - United States TSCA - Sect. 8(b) Australia (AICS):	XU Present
Sucrose Inventory - United States TSCA - Sect. 8(b) Australia (AICS): REACH - Annex IV - Exemptions from the obligations of Register: EU EINECS/ELINCS List	Present Present Present 200-334-9
Sorbitol solution Inventory - United States TSCA - Sect. 8(b) Australia (AICS): REACH - Annex IV - Exemptions from the obligations of Register: EU EINECS/ELINCS List	Present Present Present 200-061-5
Alcohol California Proposition 65 Inventory - United States TSCA - Sect. 8(b) Australia (AICS): EU EINECS/ELINCS List	developmental toxicity, initial date 10/1/87 (when in alcoholic beverages) Present Present 200-578-6
Water Inventory - United States TSCA - Sect. 8(b) Australia (AICS): REACH - Annex IV - Exemptions from the obligations of Register: EU EINECS/ELINCS List	Present Present Present 231-791-2

# **16. OTHER INFORMATION**

## Text of R phrases mentioned in Section 3

# Material Name: Mefenamic Acid Oral Suspension Revision date: 05-Mar-2008

R11 - Highly flammable. R22 - Harmful if swallowed. R23 - Toxic by inhalation. R35 - Causes severe burns. R63 - Possible risk of harm to the unborn child. **Data Sources:** Publicly available toxicity information. Safety data sheets for individual ingredients. Pfizer proprietary drug development information.

Prepared by:

Toxicology and Hazard Communication Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without a warranty of any kind, expressed or implied.

#### End of Safety Data Sheet